À PROPOS DE CET ÉPISODE
Dr. Denis Fompeyrine is the Founder and CEO of MyndBlue, a medical technology company developing an objective, continuous monitoring system that uses wearable devices to gather medical-grade biosignals to treat major depressive disorder. By collecting daily, passive measurements of depression severity, the platform can process this longitudinal data to create personalized biosignatures that enable early detection of relapse and treatment response. The technology aims to bring depression monitoring in line with monitoring chronic diseases like diabetes and other conditions with fluctuating severity.
Denis explains, "Our mission is to improve treatment outcomes and help patients with major depressive disorder regain their quality of life. And to achieve this, we are offering daily monitoring of depression severity. When someone is living with depression, treatment often takes place over many months. The information we need is not only obtained during periodic assessments, because patients are living with depression every day for months, typically around eight to twelve months. Clinicians usually see their patients only every six to eight weeks for about 30 minutes."
"Our medical technology collects physiological signals during normal daily life, and we use them to monitor how the patient's condition changes over time. Patients remain under the care of their clinician, and our role is simply to provide tools that complement the clinical assessment with an objective and continuous view of how the patient evolves over time. In short, we want to give depression care what every other chronic disease already has: a daily objective measure. "
#MyndBlue #MentalHealth #DigitalHealth #AIinHealthcare #HealthcareInnovation #MajorDepressiveDisorder #Depression #PTSD #WearableTechnology #Biosignatures #PrecisionMedicine #Psychiatry #VeteransHealth #Psychotherapy #RelapsePrevention #QualityOfLife #PassiveMonitoring